Analysis for JNJ

📈 Growth & Financial Trajectory

Over 8 quarters, revenues rose from about $22.45B to $24.06B, a roughly 7% advance. Net income attributable to parent progressed from about $4.69B to $5.24B, with a notable one-off spike in 2025-Q1 (~$11B) that is not representative of ongoing profitability; excluding that quarter, earnings show steady growth.

💰 Margins & Cash Flow

Gross margins run around 67%-70%; operating margins in the mid-teens on a consistent basis, signaling strong core profitability and operating leverage. Cash flow from operations is generally positive across periods (roughly $4B-$9B per quarter), with investing and financing activity creating variability; overall free cash flow remains ample.

🛡️ Balance Sheet & Liquidity

Balance sheet is asset rich, with total assets around $180B-$200B and liquidity adequate: cash around $18B-$22B and current assets around $54B-$59B versus current liabilities around $50B-$58B, yielding a comfortable working-capital cushion. Debt levels are substantial but offset by scale and earnings power.

⚠️ Key Drivers & Risks

• Drivers: Ongoing pharmaceutical and consumer health demand; strong cash generation supports dividends and share repurchases.
• Risks: Regulatory and litigation exposure and valuation sensitivity to interest rates; cyclicality could drive quarterly variability.